


Emergent BioSolutions Product Portfolio

As of September 2008



¹ Pivotal studies in animals and humans expected to proceed in parallel under the FDA animal rule.

² Licensed to Oxford-Emergent Tuberculosis Consortium Ltd. from Isis Innovation Ltd., the commercialization arm of Oxford University.

ALL INVESTIGATIONAL PRODUCTS MUST SUCCESSFULLY COMPLETE THEIR RESPECTIVE DEVELOPMENT PROGRAMS AND BE APPROVED BY THE FDA (AND/OR FOREIGN EQUIVALENTS) BEFORE THEY MAY BE MARKETED.